- Home
- XBIO vs APM Comparison
XBIO vs APM Comparison
Compare XBIO & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- APM
- Stock Information
- Founded
- XBIO N/A
- APM 2010
- Country
- XBIO United States
- APM United Kingdom
- Employees
- XBIO N/A
- APM N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- XBIO Health Care
- APM Health Care
- Exchange
- XBIO Nasdaq
- APM Nasdaq
- Market Cap
- XBIO 5.8M
- APM 6.7M
- IPO Year
- XBIO N/A
- APM 2018
- Fundamental
- Price
- XBIO $2.67
- APM $0.88
- Analyst Decision
- XBIO Hold
- APM
- Analyst Count
- XBIO 1
- APM 0
- Target Price
- XBIO N/A
- APM N/A
- AVG Volume (30 Days)
- XBIO 6.9K
- APM 27.5K
- Earning Date
- XBIO 03-18-2025
- APM 04-29-2025
- Dividend Yield
- XBIO N/A
- APM N/A
- EPS Growth
- XBIO N/A
- APM N/A
- EPS
- XBIO N/A
- APM 0.00
- Revenue
- XBIO $2,500,284.00
- APM N/A
- Revenue This Year
- XBIO N/A
- APM $157,729.10
- Revenue Next Year
- XBIO $27.78
- APM N/A
- P/E Ratio
- XBIO N/A
- APM $242.56
- Revenue Growth
- XBIO N/A
- APM N/A
- 52 Week Low
- XBIO $2.26
- APM $0.46
- 52 Week High
- XBIO $5.20
- APM $11.19
- Technical
- Relative Strength Index (RSI)
- XBIO 27.60
- APM 42.47
- Support Level
- XBIO $3.25
- APM $0.85
- Resistance Level
- XBIO $3.43
- APM $1.00
- Average True Range (ATR)
- XBIO 0.24
- APM 0.07
- MACD
- XBIO -0.08
- APM 0.00
- Stochastic Oscillator
- XBIO 25.63
- APM 39.15
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.